Success Stories: TEVA Sicor Biotech - PLEF

kettleitchyΒιοτεχνολογία

5 Δεκ 2012 (πριν από 4 χρόνια και 10 μήνες)

287 εμφανίσεις

LITHUANIA: BIOTECHNOLOGY


Vladas

Algirdas

Bumelis

President of


Santara

Valley“

association

History of Biotechnology in Lithuania

1970

1975

1984

1989

1990’s

2000’s

2008

2012

1970

1975

1984

1989

1990’s

2000’s

2008

2012

1
st

Biotechnology
plant
was
established


Institute of
Applied
Enzymology

was established

Recombinant
interferon
α
-
2b
approved for
human use.


The
5
th

biopharmaceutical in
the World

Development of
biopharmaceuticals
was started

1
st

c
GMP
-
compliant
multipurpose
biopharmaceutical
production facility was
established

Several
Biotechnology
companies

were
established


1
st


biopharmaceutical
product produced in
Lithuania was
approved by
FDA

1
st

biopharmaceutical
product
produced in
Lithuania was approved
by
EMEA

Life Sciences in Lithuania today


20%
annual growth



10 biotechnology companies
→ 8 specialize in
pharmaceuticals



Total annual revenues >
$ 105 million



9
0%
of biotechnology production is exported to >
70 countries


Annual average export growth


16.1%

(average export growth of total Lithuanian origin goods


10.2%)



Key strengths:


Pharmaceutical proteins


Chemistry and biochemistry of enzymes and nucleic acids


Regents and tools for molecular biology


Highly Educated and Multilingual Talent Pool


1
st

in EU
for share of graduates in total population



6
th

in EU
for language knowledge



half of the population speaks at least two foreign languages



16 academic institutions



1,800 life science students
at universities and colleges

→ 400 graduates each year



36 medals
at International high school Science Competitions
in the fields of chemistry and biology in the last few years

Advanced Research Base


16 R&D
centres

(incl. 5 major Universities)



A pool of
18,000 researchers and specialists
in life sciences



Average annual growth of funds allocated to R&D


34%



Investment into R&D infrastructure in universities

(new facilities, cutting edge technologies)
>
$ 525 million
since 2009



Biotechonological

and biochemical research conducted at:


The Institute of Biotechnology (Vilnius University)


The Institute of Biochemistry (Vilnius University)


The Institute of Chemistry (Centre for Physical Sciences and Technology)


Kaunas University of Technology


Centre of Innovative Medicine


Private research
centres



Science and Business Valleys


5 integrated science, study and business valleys
, designated for

young innovative companies and academic entities:

Valley,

location

MTEP

directions

Funding,


million, $

Santara
Valley


Vilnius

Biotechnology

Innovative

Medical

Technologies

Molecular

Medicine

125,51

Sunrise Valley

Vilnius

Laser and Light technologies

Material Sciences

Nanotechnologies

122,22

Santaka

Valley

Kaunas

Sustainable chemistry and pharmaceuticals

Future Power Engineering

96,52

Nemunas

Valley

Kaunas

Agro

biotechnology

Food

technology

72,16

Maritime Valley

Klaip
ė
da

Marine
Environment

Coastal

research

78,46

Source: http://www.smm.lt/en/smt/valleys.htm

Lithuanian Innovation Strategy 2010
-

2020


Lithuanian Innovation Strategy for the Year 2010
-
2020

distinguish high
-
potential sectors:


B
iotechnology
and laser technology


I
ndustry of electricity and optical equipment


Clean technologies


F
uture energies


C
reative industries


W
elfare and wellness


Favorable environment for R&D


Lithuania provides
attractive financial incentives
for companies to finance their R&D efforts

and
offers the most favorable tax regime for R&D activities in the
EU:


Expenses
incurred by companies carrying out R&D projects

can
be
deducted

from taxable income
three
times


Long
-
term
assets used in the R&D activities can be

depreciated
within two
years


Companies
carrying out investments into new technologies

can
reduce

their
taxable
income
by up to 50
%


Investment
expenses exceeding this sum can be

postponed
to later
, consecutive tax periods (up to five years
)




Success Stories: TEVA
Sicor

Biotech


Lithuanian
Sicor

Biotech was
acquried

by
Teva

Pharmaceutical Industries in
2006


190 employees

(+50 more to be hired once the new manufacturing facility in Vilnius has been built)


The
only company in Eastern Europe
that develops and produces modern recombinant biopharmaceutical products


TevaGrastim
©, a medicine
used to stimulate the production of white blood
cells, that is
30% cheaper
than similar drugs on the
market, but
just as effective


Research in biochemistry, molecular biology, modern gene engineering, biosynthesis,
biopharmacy


Produces recombinant proteins for medical use


Products approved by EMEA in 2008


Filgrastim

product registered
by the US Food and Drug
Administration (FDA) in 2012

Success Stories:
ThermoFisher

Scientific


The world’s leader in molecular biology acquired Lithuanian Fermentas in 2010


400 employees
→ 100 of R&D staff


Significant expertise in molecular biology and enzymology:


Discovering restriction enzymes


Genetic engineering


Protein purification


Nucleic acid purification and transfection


A comprehensive line of production distributed in over 70 countries


Extensive R&D experience and state
-
of
-
the
-
art facilities in Lithuania


September 2012: opening of a new manufacturing plant and R&D facility (10,000 sqm)

THANK YOU!